Axsome Therapeutics, Inc. (AXSM) Stock: Price, Forecast & Analyst Target
Axsome Therapeutics, Inc. (AXSM) — MoonshotScore 33/100 (Weak band), calculated Oct 4, 2026. Price $179.25 (-1.55%), as of the Oct 2, 2026 trading session; market cap $9.39B. Expected results Nov 2, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Axsome Therapeutics, Inc. · AXSM · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Axsome Therapeutics is a commercial biopharmaceutical company selling central nervous system medicines while advancing a broad clinical pipeline across depression, migraine, sleep disorders, pain and neuropsychiatric conditions. The case depends on whether product revenue can outgrow the commercial and research spending that still keeps the business unprofitable and usually cash consumptive.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Axsome Therapeutics (AXSM)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Durable growth, though the balance sheet is only middling. Business Quality: Average; Financial Safety: Okay; Valuation: Full; Growth Durability: Growing; Momentum: Rising.
- quarterly revenue $218M (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 3 of 8
- Altman Z 6.07 · Piotroski F 3
Helping: durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 33 | Weak | |
| 33 | Weak | |
| 33 | Weak | |
| 33 | Weak | |
| 33 | Weak | |
| 33 | Weak |
The score was 33 in the stored Oct 3, 2026 snapshot and remains 33 in the current publication computed Oct 4, 2026 (0); the largest pillar moves were Financial Safety -1 and Momentum +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $179.25 | |
| Change on the day | -1.55% | |
| 52-week range | $117.30–$260.19 | |
| Market capitalisation | $9.39B | |
| Price / earnings (trailing) | 39.83 | |
| Shares traded on the day | 981.4K | |
| Beta (volatility vs the S&P 500) | 0.6 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
The provider's estimated date can change.
What to watch nextCouncil Score · weighted blend of 2 available disciplines
Council score for Axsome Therapeutics (AXSM): Split View
47/100 · CSome lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
2 lenses, 2 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 4, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company more favourably than the MoonshotScore does: Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 4, 2026, except a card that shows its own read date.
Watch the AXSM film — every key number, told as a short cinematic story
~2 min · open the film
What is Axsome Therapeutics (AXSM), and what does it report?
Short answer · as of
Axsome is no longer simply a clinical-stage biotechnology developer.
Research dated 2026-09-13.
Axsome is no longer simply a clinical-stage biotechnology developer. Reported revenue comes from product sales, while its development portfolio seeks additional uses and treatments across central nervous system disorders.
The financial statements therefore capture two businesses at once: a commercial operation building product demand and a research organization funding late-stage programs. Revenue has expanded sharply, but selling and administrative expense now outweighs research spending by a wide margin, making commercial efficiency increasingly important.
What do the latest results show for Axsome Therapeutics (AXSM)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $218M.
Research dated 2026-09-13.
The latest period brought renewed sequential revenue growth, higher gross profit and narrower operating and net losses. Revenue reached the strongest level in the reported quarterly series after a brief pullback, extending the substantial expansion visible in the annual record.
The improvement was not yet clean. Selling and administrative expense continued to climb, operating cash outflow worsened, and the latest reported revenue and loss both fell short of consensus. Higher gross profit and lower research expense helped the accounting loss narrow despite the heavier commercial cost base.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
| Sep 30, 2025 | Not available | Not available | Not available | Not available |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $216.35M Aug 10, 2026
- Latest report · revenue estimate
- $221.11M Aug 10, 2026
- Latest report · revenue vs estimate
- Below estimate Aug 10, 2026
- Latest report · EPS vs estimate
- Below estimate Aug 10, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 10, 2026 | $216.35M | $221.11M | −$0.9900 | −$0.8921 |
| May 4, 2026 | $189.40M | $190.91M | −$1.2600 | −$0.8500 |
| Feb 23, 2026 | $194.69M | $193.36M | −$0.7100 | −$0.7000 |
| Nov 3, 2025 | $170.99M | $191.33M | −$0.9400 | −$0.8200 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $218M | -$51M | -$1.00 (diluted) |
| Q1 FY2026 | $191M | -$65M | -$1.26 (diluted) |
| Q4 FY2025 | $196M | -$29M | -$0.56 (diluted) |
| Q3 FY2025 | $171M | -$47M | -$0.94 (diluted) |
What are the financial strengths and risks for Axsome Therapeutics (AXSM)?
Short answer
Cash and short-term investments were $0.00 at the Jun 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13.
Liquidity exceeds total debt, leaving Axsome with net cash, and the cash balance has remained within a relatively narrow band across the reported window despite operations consuming cash in most periods. That provides room to fund commercialization and clinical work without an immediate balance-sheet constraint.
The risk sits in the conversion of growth into durable cash generation. Gross margins are high, but selling and administrative spending is rising rapidly, operating losses persist, and the market value stands far above the net cash position. A slowdown in product revenue without a matching adjustment in spending would pressure both the valuation case and the financial cushion.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Rich valuation — a P/E of 39.83 runs well above the Healthcare sector’s ~21.10x, leaving little room for a miss.
What should you watch next at Axsome Therapeutics (AXSM)?
Short answer · as of
The next earnings report is expected on Nov 2, 2026.
Research dated 2026-09-13.
The upcoming earnings report needs to be read through three linked observations: whether revenue accelerates as consensus expects, whether the loss contracts, and whether operating cash flow begins to follow the improvement in the income statement. Revenue growth accompanied by another sharp increase in commercial expense would be less persuasive than growth that narrows losses and reduces cash use.
Clinical progress also matters because Axsome’s expansion path reaches beyond current product sales. Updates involving depression, Alzheimer’s disease agitation, smoking cessation, migraine, narcolepsy or fibromyalgia could change the breadth of the future portfolio, while delays would leave more of the burden on the existing commercial business.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Axsome Therapeutics compare with its peers?
Short answer
Axsome Therapeutics's score ranks 12th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Axsome differs from a pre-revenue biotechnology developer because product sales already form a substantial and rapidly expanding business. It also differs from a mature specialty pharmaceutical company because continuing losses and a broad late-stage central nervous system pipeline still make research execution and financing discipline central to the story.
That combination produces attractive product gross margins but heavy commercial and development spending. Comparable businesses may depend mainly on trial outcomes or mainly on established brands; Axsome must prove that its commercial platform can fund continued portfolio expansion.
| Company | Price | Market value | Score |
|---|---|---|---|
| $322.28 Oct 2, 2026 | $9.54B | 97 5-pillar Oct 4, 2026 | |
| $72.40 Oct 2, 2026 | $11.3B | 93 5-pillar Oct 4, 2026 | |
| $116.23 Oct 2, 2026 | $12.6B | 91 5-pillar Oct 4, 2026 | |
| $28.30 Oct 2, 2026 | $8.00B | 89 5-pillar Oct 4, 2026 | |
| $109.86 Oct 2, 2026 | $13.0B | 88 5-pillar Oct 4, 2026 | |
| $140.06 Oct 2, 2026 | $9.01B | 76 5-pillar Oct 4, 2026 | |
| $159.56 Oct 2, 2026 | $6.40B | 69 5-pillar Oct 4, 2026 | |
| $54.29 Oct 2, 2026 | $8.31B | 65 5-pillar Oct 4, 2026 | |
| $57.18 Oct 2, 2026 | $11.1B | 65 5-pillar Oct 4, 2026 | |
| $41.75 Oct 2, 2026 | $7.00B | 64 5-pillar Oct 4, 2026 | |
| $235.67 Oct 2, 2026 | $14.8B | 40 5-pillar Oct 4, 2026 | |
| Axsome Therapeutics (AXSM) — this page | $179.25 | $9.39B | 33 |
| $64.19 Oct 2, 2026 | $9.04B | 30 5-pillar Oct 4, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $246.00 – $380.00
- Consensus target
- $281.63
- Median target
- $273.50
Consensus record · Captured .
Measured against a quoted price of $179.25 (as of Oct 2, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 3, 2026
- Transactions
- 52
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 17
- Other transactions
- 35
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
What has been published about Axsome Therapeutics (AXSM)?
Axsome Therapeutics Healthcare Stock: Key Questions Answered
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does Axsome actually sell while its CNS pipeline advances?
Reported revenue comes from product sales, while the company continues developing treatments across several central nervous system disorders. Its results therefore reflect active commercialization alongside clinical research rather than research spending alone.
Why did Axsome’s latest accounting loss narrow as cash use increased?
Higher gross profit and lower research expense more than offset the rise in selling and administrative spending, narrowing the reported loss. Operating cash outflow nevertheless increased, so the income-statement improvement had not yet translated into stronger cash generation.
Can Axsome’s cash position carry its late-stage CNS programs?
Liquidity exceeds debt and cash has been broadly stable across the reported span, providing a meaningful cushion. Operations still consume cash in most periods, so the durability of that cushion depends on product growth eventually producing sustained operating cash.
Which disorders could expand Axsome beyond its current product revenue?
The development portfolio spans depression, treatment-resistant depression, Alzheimer’s disease agitation, smoking cessation, migraine, narcolepsy and fibromyalgia. Progress across those programs could broaden the commercial base beyond the products generating revenue now.
What is the AXSM stock price today?
The last price recorded on this page for Axsome Therapeutics, Inc. (AXSM) is $179.25, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the AXSM price target?
The analyst consensus price target for Axsome Therapeutics, Inc. (AXSM) is $281.63 (range $246.00 to $380.00, median $273.50), per FMP data captured Oct 4, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (45 figures)
The 45 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | ONE World Trade Center, 29TH Floor, NEW York, NY, 10007 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "One World Trade Center, New York City, NY, 10007, US". |
FMP — 38 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $179.25 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T20:54:57.942Z. | |
px.change | Change on the day | -1.55% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalization | $9.39B | FMP | Financial Modeling Prep (FMP) quote — Provider market cap uses the share class it prices; a company with more than one class may show a larger total elsewhere. Market cap record date: 2026-10-04. Source capture time was not supplied. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
earn.next | Next earnings date | Nov 2, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.change_abs | Change on the day, in dollars | −$2.82 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $218M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $117.30–$260.19 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 39.83 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 981.4K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.6 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Herriot Tabuteau | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 1,346 | FMP | Financial Modeling Prep (FMP) company profile | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY1970 through FY2025: FY1970 revenue $0.00, net result $0.00; FY2022 revenue $0.00, net result $0.00; FY2023 revenue $0.00, net result $0.00; FY2024 revenue $0.00, net result $0.00; FY2025 revenue $0.00, net result $0.00 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.gross_margin | Gross margin (trailing twelve months) | 93.2% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
earn.history.depth.2026-08-10.revenue_actual | Revenue · reported — report date 2026-08-10 | $216.35M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-10.revenue_estimated | Revenue · estimate — report date 2026-08-10 | $221.11M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-10.eps_actual | EPS · reported — report date 2026-08-10 | −$0.9900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-10.eps_estimated | EPS · estimate — report date 2026-08-10 | −$0.8921 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-04.revenue_actual | Revenue · reported — report date 2026-05-04 | $189.40M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-04.revenue_estimated | Revenue · estimate — report date 2026-05-04 | $190.91M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-04.eps_actual | EPS · reported — report date 2026-05-04 | −$1.2600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-04.eps_estimated | EPS · estimate — report date 2026-05-04 | −$0.8500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-23.revenue_actual | Revenue · reported — report date 2026-02-23 | $194.69M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-23.revenue_estimated | Revenue · estimate — report date 2026-02-23 | $193.36M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-23.eps_actual | EPS · reported — report date 2026-02-23 | −$0.7100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-23.eps_estimated | EPS · estimate — report date 2026-02-23 | −$0.7000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-03.revenue_actual | Revenue · reported — report date 2025-11-03 | $170.99M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-03.revenue_estimated | Revenue · estimate — report date 2025-11-03 | $191.33M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-03.eps_actual | EPS · reported — report date 2025-11-03 | −$0.9400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-03.eps_estimated | EPS · estimate — report date 2025-11-03 | −$0.8200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. The market-value ratio is undefined when the reported amount is zero. | |
fin.total_debt | Total debt | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 110.82× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
earn.pt_range | Analyst price target, low to high | $246.00 – $380.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $281.63 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $273.50 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 52 transactions · 0 purchases, 17 sales, 35 other transactions · 9 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Sep 3, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 3 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-02 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 6.07 · Piotroski F 3 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 |
COMPUTED — 2 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history.depth.2026-08-10.revenue_actual.comparison | Latest report · revenue vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($216.35M) with the recorded estimate ($221.11M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-10.eps_actual.comparison | Latest report · EPS vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS (−$0.9900) with the recorded estimate (−$0.8921) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 33 of 100 · Weak · pillars 56 / 45 / 44 / 69 / 64 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 33 (stored snapshot Oct 3, 2026) → 33 (current publication computed Oct 4, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
Fact-family notes
- Earnings-history note. Source series as of 2026-08-10. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-10.revenue_actual,earn.history.depth.2026-08-10.revenue_estimated,earn.history.depth.2026-08-10.revenue_actual.comparison,earn.history.depth.2026-08-10.eps_actual.comparison,earn.history.depth.2026-08-10.eps_actual,earn.history.depth.2026-08-10.eps_estimated,earn.history.depth.2026-05-04.revenue_actual,earn.history.depth.2026-05-04.revenue_estimated,earn.history.depth.2026-05-04.eps_actual,earn.history.depth.2026-05-04.eps_estimated,earn.history.depth.2026-02-23.revenue_actual,earn.history.depth.2026-02-23.revenue_estimated,earn.history.depth.2026-02-23.eps_actual,earn.history.depth.2026-02-23.eps_estimated,earn.history.depth.2025-11-03.revenue_actual,earn.history.depth.2025-11-03.revenue_estimated,earn.history.depth.2025-11-03.eps_actual,earn.history.depth.2025-11-03.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | Product: $633.80M | 2025-12-31 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-08-10 | FMP | Financial Modeling Prep (FMP) earnings |
| Trailing twelve-month ratio set | Quick ratio: 1.34; Current ratio: 1.43; Debt to equity: 2.63; Net margin: -24.7%; Gross margin: 93.2%; Operating margin: -24.3%; Return on assets: -25.2%; Return on equity: -255.6% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Cash, investments and debt | Total debt: $219.21M; Liquidity basis: cash and short-term investments; Total liabilities: $678.14M; Cash and short-term investments: $319.85M; Cash and investments: $319.90M; Long-term investments: $0; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $319.90M; Cash and short-term investments: $319.90M; Long-term investments: $0; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash decline over the reported window | To: 2026-06-30; From: 2024-09-30; Periods: 7; Cash basis: cash and short-term investments; Closing balance: $319.90M; Decline: $7.50M; Opening balance: $327.30M; Average change per period: $1.10M Change in cash, cash equivalents and short-term investments between the 2024-09-30 and 2026-06-30 balance sheets.; This is a balance change, not operating burn: financing and investing move it too.; Averaged over 7 reporting periods of unequal length. | 2026-06-30 | COMPUTED | Computed from reported balances |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: $100.60M; Total debt: $219.20M; Cash and investments: $319.90M Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Next earnings report | Date: 2026-11-02; EPS estimate: -$0.48897 per share; Revenue estimate: $258.28M The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Sector / industry (provider taxonomy) | Healthcare / Biotechnology The company's SEC filings classify it under SIC 2834 — Pharmaceutical Preparations. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
Data provided for informational purposes only.
ETFs that hold AXSM
Funds in our ETF coverage that list AXSM among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| iShares Neuroscience and Healthcare ETF (IBRN) | 4.53% |